The recent suspension of a proposed hepatitis B birth-dose vaccine trial in Guinea-Bissau has prompted critical reflection across the global research community. At Pharmalys, we believe this moment represents both a warning and an opportunity: a reminder that Africa can and should be a powerful accelerator for high quality clinical data, but never at the expense of ethical standards or community trust.
A proven intervention should never be withheld
The hepatitis B birth-dose vaccine is not experimental; it is a well-established, life saving intervention. For more than 30 years, it has been safely used around the world to prevent mother-to-child transmission of hepatitis B, a major contributor to cirrhosis and liver cancer. Over 115 countries have already incorporated the birth dose into their national immunisation schedules, recognising its unquestionable public health value.
Against this backdrop, the design of the proposed Guinea-Bissau trial – which would have provided the birth dose to some newborns while withholding it from others – raises serious ethical concerns. With decades of proven benefit, there is no scientific or moral justification for a no-treatment arm. Exposing infants to preventable lifelong harm contradicts the foundational principles of ethical research.
A standard we must uphold
The planned trial highlights the importance of adhereing to internationally recognised ethical frameworks such as the ICH Good Clinical Practice (GCP) guidelines. These principles exist precisely to prevent situations where participants are exposed to avoidable harm or denied established, effective interventions.
The most recent update, ICH GCP(R3), reinforces that ethical conduct is both universal and uncompromisable. It strengthens expectations around:
- Ensuring participants are not deprived of proven, beneficial treatments when such interventions already exist.
- Minimising risk and ensuring a clear prospect of benefit for all individuals involved in a study.
- Embedding respect for participants and their communities, placing their welfare, rights, and dignity at the centre of research decisions.
No matter where research takes place, these standards apply universally.
Africa as an engine for high quality, ethical research
Africa possesses enormous potential to accelerate global scientific understanding. Its demographic diversity, disease burden, and rapidly expanding research infrastructure create an unparalleled environment for generating meaningful clinical evidence. But this potential can only be realised through research models rooted in transparency, respect, and community partnership.
Unethical trial designs undermine trust and risk setting back decades of progress. Ethical vigilance, on the other hand, strengthens Africa’s position as a leader in high impact, high integrity clinical research.
Pharmalys commends both Guinea-Bissau’s national authorities and international health bodies for acting quickly by suspending the trial pending further review. Their decision demonstrates a commendable commitment to protecting newborns and ensuring that all research conducted in the country aligns with global scientific and ethical expectations.
The suspension also outlines Guinea-Bissau’s ongoing progress. The country formally decided in 2024 to introduce the hepatitis B birth-dose vaccine nationwide by 2028, a clear recognition of its value, and another reason why withholding it from research participants would not be ethically acceptable.
Our call to the research community
As partners in global health research, we have a shared responsibility to ensure that innovation never comes at the expense of ethics. This moment should serve as a call to action for sponsors, investigators, ethics committees, and regulatory authorities to:
- Uphold ICH GCP(R3) principles in every study, regardless of geography
- Refuse trial designs that withhold proven care
- Promote research approaches that offer real value to participating communities
- Strengthen capacity building and ethical oversight across the African continent
By doing so, we can create a research environment where Africa continues to contribute powerful, high quality data, while protecting the dignity, safety, and rights of every participant. It is essential that we Count Africa In as a full and valued partner in global clinical research.
Source: World Health Organization, Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau, 13 Feb 2026 https://www.who.int/news/item/13-02-2026-statement-on-the-planned-hepatitis-b-birth-dose-vaccine-trial-in-guinea-bissau
